Who benefits from Helicobacter pylori eradication?

British Medical Journal

Volumn 332, Issue 7535, 2006, Pages 187-188

  Delaney, Brendan C ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

CLINICAL FEATURE; COST BENEFIT ANALYSIS; COST CONTROL; DIAGNOSTIC ACCURACY; DRUG COST; DRUG EFFICACY; DUODENUM ULCER; DYSPEPSIA; EDITORIAL; EPIGASTRIC PAIN; ERADICATION THERAPY; FECES ANALYSIS; GASTROSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MONEY; OUTCOME ASSESSMENT; PEPTIC ULCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; SCREENING TEST; SYMPTOM; TREATMENT PLANNING; UREA BREATH TEST;

DYSPEPSIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER;

EID: 31644434694     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.332.7535.187     Document Type: Editorial

References (12)

1. Talley NJ. Review article: dyspepsia: how to manage and how to treat? Aliment Pharmacol Ther 2005;16:95-104.
2. Chiba N, Veldhuyzen van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dypsepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002;324:1012-5.
3. Mason JM, Delaney B, Moayyedi P, Thomas M, Walt R, North of England Dyspepsia Guideline Development Group. Managing dyspepsia without alarm signs in primary care: new national guidance for England and Wales. Aliment Pharmacol Ther 2005;21:1135-43.
4. Ford A, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2003(4):CD003840.
5. Moayyedi P, Deeks JJ, Talley NJ, Delaney BC, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia; resolving the discrepancy between the systematic reviews. Am J Gastroenterol 2003;98:2621-6.
6. Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004;127:1329-37.
7. Delaney BC, Moayyedi P. Eradicating H pylori does not cause gastro-oesophageal reflux disease. BMJ 2004;328:1388-9.
8. Talley NJ, Vakil N, Delaney B, Marshall B, Bytzer P, Engstrand L, et al. Management issues in dyspepsia: current consensus and controversies. Scand J Gastroenterol 2004;39:913-8.
9. Ford AC, Qume M, Moayyedi P, Arents NL, Lassen AT, Logan RF, et al. Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005;128:1838-44.
10. Mason J, Axon AT, Forman D, Duffet S, Drummond M, Crocombe W, et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther 2002;16:559-68.
11. Lane JA, Murray LJ, Noble S, Egger M, Harvey IM, Donovan JL, et al. Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol helicobacter project: randomised controlled trial. BMJ 2006;332:199-202.
12. Chiba N, Veldhuyzen van Zanten SJ, Escobedo S, Grace E, Lee J, Sinclair P, et al. Economic evaluation of Helicobacter pylori eradication in the CADET-HP randomised controlled trial of H pylori positive primary care patients with uninvestigated dyspepsia. Aliment Pharmacol Ther 2005;19:349-58.